


Substitute for form 1449A/PTO & 1449B/PTO				<i>Complete if Known</i>	
SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/763,539
				Filing Date	January 26, 2004
				First Named Inventor	Steve J. KARLIK.
				Examiner Name	Shaojia A. Jiang
Sheet	1	of	1	Attorney Docket Number	1002010-000854
 NOV 28 2006					



U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/CH/	N. Tubridy et al., "THE EFFECT OF ANTI-[ALPHA]4 INTEGRIN ANTIBODY ON BRAIN LESION ACTIVITY IN MS", Neurology, Vol. 53, No. 3, pp. 466-472, August 1999.
/CH/	Franz X. Weilbach et al., "DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS. WHAT IS ON THE HORIZON?", CNS Drugs, Vol. 11, No. 2, pp. 133-157, February 1999.
/CH/	W. A. Sheremata et al., "A SAFETY AND PHARMACOKINETIC STUDY OF INTRAVENOUS NATALIZUMAB IN PATIENTS WITH MS", Neurology, Vol. 52, No. 5, pp. 1072-1074, March 1999.
/CH/	Syed A. Rizvi et al, "OTHER THERAPY OPTIONS AND FUTURE STRATEGIES FOR TREATING PATIENTS WITH MULTIPLE SCLEROSIS", Neurology, Vol. 63, (Suppl 6), pp. S47-S54, December 2004.

Examiner Signature	/Carlic Huynh/	Date Considered	05/10/2007
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.